Navigation Links
GlySure Earns ISO 13485 Certification
Date:3/5/2013

OXFORD, England, March 5, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.

"This is an exciting time for our company as we conclude our prototype trials and turn our sights toward securing a CE mark," said GlySure CEO Chris Jones . "ISO 13485 certification is a key step in this transition as it validates our quality management system and ability to consistently deliver safe and effective technologies to the global marketplace."

GlySure's continuous blood glucose monitoring (CBGM) technology meets the clinically documented need for Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU), which has been shown to improve outcomes, reduce mortality and cut the cost of care.

ISO certification is the latest in a series of recent key achievements for GlySure as it prepares for regulatory trials. Over the past year the company has expanded its manufacturing, quality and development teams, opened a new manufacturing facility in Oxfordshire, England and is nearing completion of pre-clinical trials in over 120 ICU patients. GlySure anticipates that it will begin CE mark trials of its CGM system in the second quarter of 2013.

For more information on GlySure, TGC and CBGM technology, visit http://www.glysure.com.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 23 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones , CEO, GlySure. Tel: +44(0)1235-462-870. cjones@glysure.com
Media Contact: Bruce Dodworth , Sea Glass PR. Tel: +44(0)1780-758555. bruce@seaglasspr.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
2. ZirMeds SaaS Solution Earns EHNAC HNAP Certification
3. Cardiac Science Earns Top Marks for Cardiac Stress Test, Telemetry Monitor Systems
4. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
5. MedicareBlue Rx Drug Plan Earns Federal Governments Top Rating
6. Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
7. Plainfield Precision Achieves ISO 13485:2003 Quality Management Certification for Medical Device Manufacturing
8. Solos Endoscopy and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013
9. MDI Announces ISO 13485 Certification
10. GPMG Product Helps Medical Device Specification Developers be FDA and ISO 13485 Compliant
11. PDR and the iHealth Alliance Announce New Drug Safety Certification for EHRs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):